Fairvalue-Calculator Fairvalue-Calculator
EN DE

NovoCure Limited (NVCR) Fair Value & Analysis

Healthcare · US · Market cap $1.7B

Price$14.13
Fair Value$13.23
Upside-6.4%
Quality95/100
Evidence: Low Range $9.92 – $16.54

Fair value as of: Jun 24, 2026

Analysis

NovoCure Limited (NVCR) currently trades at $14.13, while our model-based Fair Value estimate is $13.23 — implying the stock looks roughly 6.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABTT34) -83% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -81% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is NovoCure Limited (NVCR) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $13.23 versus a price of $14.13 — about −6% (overvalued). Model-based estimate, not financial advice.
What is the fair value of NVCR?
Our 21-model fair value for NovoCure Limited is $13.23 (as of Jun 24, 2026), built from audited fundamentals. The current price is $14.13.
What is the quality score of NVCR?
NovoCure Limited has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.